SIDEBAR 2.3Targeted Radionuclide Therapy

Targeted radionuclide therapy is a form of treatment that delivers therapeutic doses of radiation to malignant tumors by administering a molecule that is labeled with a radionuclide. The radiotherapeutic agent is made of two components: the radionuclide and the carrier that is used to seek out the tumor cells. Molecular carriers that can be used include, but are not limited to, peptides that seek their corresponding receptors on cells, and monoclonal antibodies that seek out antigens that are similarly expressed on the cells, as shown in the figure.

FIGURE. Schematic of a tumor cell expressing targets for a radiotherapeutic agent.


Schematic of a tumor cell expressing targets for a radiotherapeutic agent. SOURCE: Courtesy of Michael Zalutsky, Duke University.

The radionuclide that is attached to the carrier molecule can be chosen for specific characteristics, such as type of radiation decay (e.g., alpha-emitter, beta-emitter), radiation range, and half-life. It is this modular nature, where the two components can be varied like Lego® pieces to match characteristics specific to the tumor that makes targeted radionuclide therapy an attractive approach to cancer treatment (Zalutsky 2003). To date, two antibody radiopharmaceuticals have been approved by the FDA (yttrium-90-ibritumomab tiuxetan and iodine-131-tositumomab) for the treatment of lymphoma.

From: 2, Nuclear Medicine

Cover of Advancing Nuclear Medicine Through Innovation
Advancing Nuclear Medicine Through Innovation.
National Research Council (US) and Institute of Medicine (US) Committee on State of the Science of Nuclear Medicine.
Washington (DC): National Academies Press (US); 2007.
Copyright © 2007, National Academy of Sciences.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.